Badovinac, Vladimir P

Primary and metastatic brain tumors exhibit resistance to immunotherapies that demonstrate efficacy in peripheral cancer settings. While many immunotherapies aim to enhance CD8 + T cell infiltration and functionality in established tumors, identification of neoantigens support emerging immunopreventative tactics against brain cancer. Functionally potent tissue-resident memory CD8 + T cells (T RM ) can be generated in the brain following peripheral infection or vaccination. However, the ability of brain T RM to prevent intracranial malignancy remains unknown. Here, mice were seeded with tumor-specific or bystander brain T RM via peripheral infection prior to depletion of circulating memory T cells (T CIRCM ) and subsequent brain tumor challenge. Tumor-specific brain T RM durably protected mice against intracranial malignancy even in the absence T CIRCM . These brain T RM persisted in tumor-surviving mice and protected against a second antigen-matched challenge. Importantly, a translationally-relevant mRNA-lipid nanoparticle (LNP) vaccine phenocopied peripheral infection-induced outcomes, generating functional brain T RM that controlled tumor growth. Altogether, this work points to the utility of brain T RM in cancer immunoprevention, supporting the development of antitumor mRNA-LNP vaccines to bolster brain immunity.

Abstract Description Sepsis, the life-threatening organ dysfunction stemming from the severe inflammatory response to systemic microbial infection, can affect humans of any age. One consequence of sepsis is the development of prolonged immunoparalysis that contributes to increased susceptibility to infection. With vaccination being an important means for protecting humans from infection throughout their lifetime, it is surprising that there has been no study performed to date assessing vaccine efficacy in sepsis survivors. We found neonatal and adult mice given an intramuscularly delivered inactivated multivalent influenza vaccine 30 days after sepsis induction had reduced total and class switched Ab titers, compared to non-septic controls. The reduced humoral response was due, in part, to impaired CD4 T cell and B cell responses to the vaccine. Reduced Ab titers were similarly seen in post-septic mice given an intranasal live-attenuated influenza vaccine. ELISpot data demonstrating reduced numbers of antibody secreting cells in the spleens of vaccinated septic mice further support the ELISA results. Moreover, mice vaccinated prior to sepsis induction also showed reduced antibody titers. Importantly, vaccinated septic mice had reduced protection to a lethal influenza challenge, demonstrated by increased mortality and viral burden in the lungs. These data collectively show how sepsis can lead to increased susceptibility to pathogens normally neutralized by vaccine-induced immunity. Funding Sources Supported by NIH/NIAID R35 GM140881; 5R01 GM139046; 1T32TR004385 Topic Categories Translational and Interventional Immunology (TI)

Abstract Sepsis can result from a variety of pathogens, originating from a range of sources. A vast range of presenting symptoms is included in the catch-all term of “bacteremia,” making diagnosis and prognosis particularly troublesome. One underexplored factor contributing to disparate outcomes is the age of the patient. Neonatal sepsis in very-low-birth-weight infants can result in vastly different immunological outcomes unique from sepsis in adults. It is also becoming increasingly clear, both from preclinical experimental models and clinical observations, that the age and history of previous microbial exposures can significantly influence the course of infection from sepsis and cytokine storms to immunopathology. In this study, we will explore key differences between neonatal and adult sepsis, experimental models used to study sepsis, and how responses to the surrounding microbial universe shape development of the immune system and impact, positively or negatively, the course of disease.